A
Abid Mohiuddin
Researcher at University of Arkansas for Medical Sciences
Publications - 15
Citations - 1979
Abid Mohiuddin is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Survival rate. The author has an hindex of 9, co-authored 15 publications receiving 1869 citations. Previous affiliations of Abid Mohiuddin include Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy,Fenghuang Zhan,Bart Burington,Yongsheng Huang,Simona Colla,Ichiro Hanamura,James P. Stewart,Bob Kordsmeier,Christopher Randolph,David R. Williams,Yan Xiao,Hongwei Xu,Joshua Epstein,Elias Anaissie,Somashekar G. Krishna,Michele Cottler-Fox,Klaus Hollmig,Abid Mohiuddin,Mauricio Pineda-Roman,Guido Tricot,Frits van Rhee,Jeffrey R. Sawyer,Yazan Alsayed,Ronald C. Walker,Maurizio Zangari,John Crowley,Bart Barlogie +26 more
TL;DR: The data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.
Journal ArticleDOI
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Ronald C. Walker,Bart Barlogie,Jeffrey Haessler,Guido J Tricot,Elias Anaissie,John D. Shaughnessy,Joshua Epstein,Rudy Van Hemert,Eren Erdem,Antje Hoering,John Crowley,Ernest Ferris,Klaus Hollmig,Frits van Rhee,Maurizio Zangari,Mauricio Pineda-Roman,Abid Mohiuddin,Shmuel Yaccoby,Jeffrey Sawyer,Edgardo J. Angtuaco +19 more
TL;DR: MRI is a more powerful tool for detection of FLs than is MBS and is recommended that, in addition to MBS, MRI be used routinely for staging, prognosis, and response assessment in myeloma.
Journal ArticleDOI
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie,Elias Anaissie,Frits van Rhee,Jeffrey Haessler,Klaus Hollmig,Mauricio Pineda-Roman,Michele Cottler-Fox,Abid Mohiuddin,Yazan Alsayed,Guido Tricot,Vanessa Bolejack,Maurizio Zangari,Joshua Epstein,Nathan Petty,Douglas Steward,Bonnie Jenkins,Jennifer Gurley,Ellen Sullivan,John Crowley,John D. Shaughnessy +19 more
TL;DR: Results of this phase‐2 study demonstrated that bortezomib could be safely combined with multi‐agent chemotherapy, effecting near‐complete remission status and 2‐year survival rates in more than 80% of patients.
Journal ArticleDOI
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
Frits van Rhee,Vanessa Bolejack,Klaus Hollmig,Mauricio Pineda-Roman,Elias Anaissie,Joshua Epstein,John D. Shaughnessy,Maurizio Zangari,Guido Tricot,Abid Mohiuddin,Yazan Alsayed,Gail L. Woods,John Crowley,Bart Barlogie +13 more
TL;DR: Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease- and steeper reductions after therapy identified patients with inferior survival.
Journal ArticleDOI
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Jeff Haessler,John D. Shaughnessy,Fenghuang Zhan,John Crowley,Joshua Epstein,Frits van Rhee,Elias Anaissie,Mauricio Pineda-Roman,Maurizio Zangari,Klaus Hollmig,Abid Mohiuddin,Yazan Alsayed,Antje Hoering,Guido Tricot,Bart Barlogie +14 more
TL;DR: Access to gene expression information permitted the recognition of a small very high-risk subgroup of 13% of patients, in whom prolonged survival critically depended on achieving CR, which should lead to a reassessment of clinical trial designs that rely on this end point as a surrogate for long-term prognosis.